Equities

Evolus Inc

Evolus Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.44
  • Today's Change-0.68 / -5.18%
  • Shares traded821.00
  • 1 Year change+55.50%
  • Beta1.2670
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

  • Revenue in USD (TTM)248.33m
  • Net income in USD-55.46m
  • Incorporated2012
  • Employees322.00
  • Location
    Evolus Inc520 Newport Center Dr Ste 1200NEWPORT BEACH 92660-7022United StatesUSA
  • Phone+1 (949) 284-4555
  • Fax+1 (302) 636-5454
  • Websitehttps://www.evolus.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SNDL Inc653.48m-79.20m531.00m2.52k--0.6126--0.8126-0.3022-0.30222.483.260.60624.9836.38259,731.60-7.61-24.44-8.22-27.9425.6922.49-12.55-62.174.16--0.114--27.63--49.83------
ASP Isotopes Inc2.30m-27.05m567.17m76.00--37.73--247.06-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Emergent Biosolutions Inc1.13bn-208.80m590.07m1.60k--1.16--0.5243-4.10-4.1021.199.400.66782.216.66703,437.50-12.39-2.94-16.86-3.6633.5153.24-18.55-5.951.47-1.190.5658---6.106.05-259.40---4.29--
Elite Pharmaceuticals Inc66.45m19.58m598.34m64.0029.2810.2728.419.000.01910.01910.0640.05450.98922.914.981,038,252.0029.1519.0736.1824.2945.2746.6329.4720.772.091.440.13890.0065.7949.55464.56--111.50--
Sinovac Biotech Ltd429.20m-130.73m639.90m3.04k------1.49-1.31-1.314.3186.810.03220.20191.08141,325.00-2.2336.14-3.3058.3792.0990.77-69.1965.8711.24--0.0262---69.9714.31-198.16--91.80--
Phathom Pharmaceuticals Inc26.27m-339.45m650.95m452.00------24.78-5.69-5.690.4398-2.740.08422.68--58,119.47-108.79-83.26-126.95-93.7783.54---1,292.14-135,982.005.68-5.601.56-------1.96------
CorMedix Inc12.26m-46.15m708.10m82.00--11.51--57.75-0.8011-0.80110.2121.010.1451----149,539.50-54.61-54.84-64.60-62.3283.576.18-376.35-18,323.423.60--0.00---100.00---56.02--46.27--
Eyepoint Pharmaceuticals Inc45.71m-103.57m756.55m121.00--2.72--16.55-2.01-2.010.90184.090.19831.05106.19377,793.40-44.94-40.44-59.48-47.7991.4883.45-226.57-186.235.45--0.00--11.14--30.77------
Pacira Biosciences Inc694.96m-90.73m775.71m711.00--1.03--1.12-2.15-2.1513.0316.240.45481.717.03977,436.00-5.943.35-6.833.9874.3572.63-13.068.571.89--0.43930.001.2214.88163.72--0.8761--
Avid Bioservices Inc142.36m-144.17m780.21m371.00--13.31--5.48-2.27-2.272.240.91920.36613.814.32383,714.30-37.08-0.826-57.59-1.206.2719.26-101.27-2.141.05-3.180.7343---6.2721.15-54,444.79--84.15--
Evolus Inc248.33m-55.46m787.72m322.00--133.59--3.17-0.9141-0.91414.110.09311.254.596.61909,619.10-27.90-40.92-38.48-59.7469.9465.43-22.33-80.462.23-2.040.9537--35.98--17.10--182.77--
Pliant Therapeutics Inc0.00-201.68m840.28m158.00--2.43-----3.34-3.340.005.680.00----0.00-40.90-33.24-43.90-35.39-------360.29----0.0802---83.69---30.83---16.89--
Liquidia Corp14.84m-112.11m892.91m136.00--12.95--60.17-1.57-1.570.21020.82080.0993--4.04109,117.60-75.00-55.02-87.85-62.6969.5282.18-755.46-474.595.78-29.470.578--9.7545.23-91.40--66.93--
Collegium Pharmaceutical Inc599.25m88.59m1.01bn197.0015.714.324.271.692.002.0013.057.270.42616.252.923,041,853.006.302.799.384.8062.3650.8814.785.160.88323.940.78730.0022.1715.11292.60---54.77--
Phibro Animal Health Corp1.05bn17.41m1.02bn1.94k58.383.9318.900.96970.42930.429325.826.381.082.606.75539,568.101.803.932.204.9031.4731.181.663.771.692.200.647256.454.074.21-92.59-46.356.650.8548
Data as of Nov 12 2024. Currency figures normalised to Evolus Inc's reporting currency: US Dollar USD

Institutional shareholders

46.10%Per cent of shares held by top holders
HolderShares% Held
Perceptive Advisors LLCas of 30 Jun 20245.75m9.12%
Tang Capital Management LLCas of 30 Jun 20244.85m7.68%
BlackRock Fund Advisorsas of 30 Jun 20243.51m5.57%
Nantahala Capital Management LLCas of 30 Jun 20242.91m4.61%
The Vanguard Group, Inc.as of 30 Jun 20242.83m4.48%
Great Point Partners LLCas of 30 Jun 20242.45m3.89%
Caligan Partners LPas of 30 Jun 20242.17m3.44%
Stonepine Capital Management LLCas of 30 Jun 20241.66m2.63%
DWS Investments (UK) Ltd.as of 30 Jun 20241.54m2.44%
Morgan Stanley & Co. LLCas of 30 Jun 20241.41m2.24%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.